Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if RAD001 in combination with Tarceva
(erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC). The
safety of this drug combination will also be studied.